INTRODUCTION
============

According to a 2017 report of the Ministry of Health and Welfare of Korea, mortality due to cardiac diseases including heart failure has progressively increased ([@b17-jer-15-3-481]). The prevalence appeared to be increasing despite advances in medical therapy and cardiac surgery because of the increasing number of older adults with complex comorbidities ([@b16-jer-15-3-481]; [@b24-jer-15-3-481]).

Left ventricular assist devices (LVADs) have been shown to benefit these patients and can be used as a bridge to transplantation or destination therapy. Use of the LVAD as destination therapy has become more frequent in recent years, due to a donor organ shortage and an increasing number of older patients with terminal heart failure who are not eligible for heart transplantation. Several studies have demonstrated improved survival rates, exercise capacity and quality of life in patients with implanted LVADs ([@b9-jer-15-3-481]; [@b20-jer-15-3-481]; [@b25-jer-15-3-481]; [@b26-jer-15-3-481]). However, there is still a concern about adverse events such as infections, thromboembolic events, and mechanical failure ([@b5-jer-15-3-481]; [@b6-jer-15-3-481]; [@b14-jer-15-3-481]). Many studies have been reported by researchers in the United States or Europe because eligibility criteria for the procedure are very strict, and the procedure is not available in many countries ([@b14-jer-15-3-481]). With an increase in heart failure patients, LVADs have become an option in the Asia-Pacific region. One study reported the clinical outcomes using LVADs (HeartMate II) in Singapore ([@b19-jer-15-3-481]). Published in 2017, the registry for Mechanically Assisted Circulatory Support was the first study in Japanese patients ([@b22-jer-15-3-481]). The clinical outcomes of successful 2nd generation LVAD implantation as destination therapy were reported in 2014 and the effect of exercise-based cardiac rehabilitation was also reported in Korean patients ([@b18-jer-15-3-481]; [@b23-jer-15-3-481]).

Considering the increase in LVAD implantation in the growing population of heart failure patients, a descriptive study is needed to provide information on the clinical outcomes in Korean patients compared to those in other studies. Therefore, this study aimed to confirm the safety and efficacy of LVAD implantation in Korean patients and to provide descriptive data for clinical outcomes after LVAD implantation.

MATERIALS AND METHODS
=====================

Patient selection
-----------------

The study population included 14 patients with heart failure due to dilated cardiomyopathy or ischemic cardiomyopathy and 1 patient with septic shock. These patients had not improved despite intensive medical and/or interventional treatments. In general, the criteria for LVAD implantation were based on the patient selection criteria from the REMATCH trial ([@b14-jer-15-3-481]). Of 22 LVAD implantations as of July 2018 10 were used as a bridge to transplantation and 12 as destination therapy but only 15 patients had follow-up data available for analysis. Four patients received a Heartmate II (Thoratec Inc., Pleasanton, CA, USA) and 11 received a HeartWare (HeartWare Inc., Framingham, MA, USA). Eight patients underwent LVAD as a destination therapy and 7 as a bridge to transplantation ([Fig. 1](#f1-jer-15-3-481){ref-type="fig"}).

Exercise-based cardiac rehabilitation
-------------------------------------

Exercise therapy was started on postoperative day 3 in the intensive care unit (ICU). The first goal was to prevent pulmonary complications and to train inspiratory muscles by applying breathing exercises with a focus on incentive spirometry education. The patients were encouraged to try walking in the ICU and walking exercise was progressively increased on the ward. The exercise type and intensity progressed from bed exercise to stair use to enhance muscle strengthening. All patients participated in inpatient cardiac rehabilitation until discharge from hospital and were encouraged to enroll in outpatient cardiac rehabilitation. The cardiac rehabilitation participation was analyzed in this study.

Follow-up
---------

During hospitalization, adverse events such as death, stroke, severe right ventricular failure and LVAD-related infections (driveline exit site and pump pocket) were recorded. After discharge, patients were followed up for 12 months and adverse events after discharge, the unplanned readmission rate, median interval between discharge and first readmission, survival rate, length of stay in the ICU and hospital, New York Heart Association (NYHA) functional classification, ejection fraction, and quality of life were recorded for analysis of outcomes. The present study protocol was reviewed and approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2018-01-145-001), and the requirements for informed consents were waived due to the retrospective nature of this study.

Statistical analysis
--------------------

Continuous data are presented as mean±standard deviation or mean±standard error of the mean. Categorical data are presented as frequencies and percentages. NYHA functional classification, quality of life score, and ejection fraction were evaluated using the generalized estimating equation for repeated measure analysis. A *P*-value of \<0.05 was considered statistically significant. All data were analyzed using the SAS software version 9.4 (SAS institute Inc., Cary, NC, USA).

RESULTS
=======

Baseline patient characteristics
--------------------------------

Patient' characteristics are summarized in [Table 1](#t1-jer-15-3-481){ref-type="table"}. Mean age was 67.4±11.6 years. Four patients received HeartMate II and 11 received HeartWare devices. Dilated cardiomyopathy was the etiology of cardiac disease in 5 cases (33.3%), with ischemic cardiomyopathy in 5 (33.3%), systolic heart failure in 4 (26.7%), and septic shock with acute myocardial infarction in 1 (6.7%). Percutaneous coronary intervention had been performed in 41.2%, with coronary artery bypass grafting in 17.6%, and implantable cardioverter defibrillator implantation, permanent pacemaker placement, or aortic valve replacement in 11.8%. Cardiac resynchronization therapy had been performed in 5.9%. Other diagnoses included atrial fibrillation in 53.3%, hypertension in 33.3%, diabetes mellitus in 33.3%, and chronic kidney disease in 33.3%; risk factors associated with postoperative complications included stroke and chronic obstructive pulmonary disease in 20% ([Table 1](#t1-jer-15-3-481){ref-type="table"}).

Adverse events
--------------

Adverse events included cardiac arrhythmias (nonsustained ventricular tachycardia and atrial fibrillation), bleeding, hematoma in the driveline, abdominal or pericardial effusion, and pneumonia during hospitalization. Ventricular tachycardia (40%), and atrial fibrillation (6.7%), bleeding (40%), and effusion (33.3%) were the most common complications during hospitalization. Adverse events after discharge from the hospital included bleeding, stroke, hematoma, and effusion. The most common adverse event after discharge was gastrointestinal (46.7%) ([Table 2](#t2-jer-15-3-481){ref-type="table"}).

Cardiac rehabilitation participation rate
-----------------------------------------

All patients participated in inpatient cardiac rehabilitation after implantation according to our hospital protocol. Inpatient cardiac rehabilitation was conducted for an average of 64.5±82.1 sessions.

Readmission
-----------

The average length of stay in the ICU and hospital was 25.3±17.5 days and 103.7±51.7 days (range, 6--59 days), respectively. However, in analyzing length of stay for hospitalization, 2 patients were excluded because they remained in the hospital for 1 year. The median time until first readmission was 57.2 days. The readmission rate during the follow-up period was 77.0%, 83.3%, and 90.5% at 3, 6, and 12 months, respectively; 22 readmissions occurred in 13 patients (average: 1.7±1.3), 30 in 12 patients (2.2±2.1), and 38 in 10 patients (3.8±2.9) at 3, 6, 12 months from discharge, respectively. The most common reason for readmission was gastrointestinal bleeding ([Table 3](#t3-jer-15-3-481){ref-type="table"}).

Clinical outcomes
-----------------

The survival rate at 6 and 12 months was 100% and 89%, respectively. The mean preoperative NYHA functional classification was 3.4±0.5, with 1.9±0.3 on the postoperative day and 2.3±0.5 at postoperative 12 months. The NYHA functional classification was significantly improved on the postoperative day (*P*\<0.0001) and at postoperative 12 months (*P*\<0.0001). Cardiac function measured with ejection fraction showed significant improvement from 23.6%±7.2% on the preoperative day to 35.4%±14.2% at postoperative 1-year (*P*\<0.0018) ([Fig. 2](#f2-jer-15-3-481){ref-type="fig"}). The physical and emotional component scores were significantly decreased from 35.1± 4.4 at baseline to 21.4±7.1 at postoperative l year (*P*\<0.0001) and from 20.2±4.8 at baseline to 12.0±4.4 at postoperative l year (*P*\<0.0001), respectively. The total score of quality of life was also significantly improved at postoperative 12 months (*P*\<0.0001) ([Fig. 3](#f3-jer-15-3-481){ref-type="fig"}).

DISCUSSION
==========

This study was the first to report the long-term clinical outcomes of LVAD implantation in Korean patients. The important findings are survival rates of 100% and 89% at 6 and 12 months, respectively. Functional capacity measured using the NYHA classification and quality of life were improved after LVAD implantation. These results demonstrate that LVAD therapy is safe and effective for improving functional capacity and quality of life in Korean patients.

Patients with an implanted LVAD have shown greater improvement in cardiopulmonary function ([@b9-jer-15-3-481]; [@b20-jer-15-3-481]). Exercise training in LVAD recipients can also improve exercise capacity ([@b21-jer-15-3-481]). In the 3 months after implantation, the physical activity level increased in these patients, but thereafter remained unchanged until the 12-month follow-up ([@b9-jer-15-3-481]). The exercise-based cardiac rehabilitation program was conducted in both the inpatient phase in this study. Inpatient cardiac rehabilitation was performed for an average of 64 days in all patients, but the participation rate in outpatient cardiac rehabilitation after discharge was very low. The 6-min walk test has been generally used to evaluate exercise capacity in patients with an implanted LVAD. In this study, we could not analyze improvement in exercise capacity because the test was not routinely performed during the follow-up period. However, functional capacity measured using the NYHA classification was improved after implantation of LVAD in this study. We also found improvement in cardiac function, with an increase in ejection fraction at 12 months. Authors thought that the improvement of these factors may be associated with participation in exercise-based cardiac rehabilitation. However, further randomized controlled trial is needed to identify the effect of exercise intervention in Korean patients with an implanted LVAD.

Survival rates at 6 and 12 months were 100% and 89%, respectively, in this study. One study ([@b7-jer-15-3-481]) reported a survival rate of 75% at 6 months, and the eighth INTERMACS report (all indications, n=15,000) showed that actuarial 1-year survival for continuous-flow LVADs was 80% ([@b15-jer-15-3-481]). The survival rate in the present study was slightly higher than in a previous study ([@b7-jer-15-3-481]; [@b22-jer-15-3-481]) and the INTERMACS report ([@b15-jer-15-3-481]), but the small sample size should be considered in comparing survival rates. The most common cause of death was a neurological disorder, followed by multiple system organ failure, infection, device malfunction, and right heart failure ([@b15-jer-15-3-481]). Another study reported that infection was the most common cause of death after LVAD implantation ([@b22-jer-15-3-481]). In this study, two patients with LVAD implantation as a bridge to transplantation died due to acute heart failure and sarcoma at postoperative 252 and 315 days, respectively. Further study is needed with a larger sample size of Korean patients to analyze the differences between Korean data and other studies.

In the present study, the average length of stay in the ICU and hospital was 25 and 104 days, respectively. A study ([@b4-jer-15-3-481]) reported a median hospital length of stay of 20 days; risk factors for longer hospital stay included age over 64 years, history of coronary artery bypass graft, history of valve surgery, diabetes mellitus, ascites, and concomitant surgery. The present study showed a longer length of stay than in previous studies ([@b1-jer-15-3-481]; [@b4-jer-15-3-481]). The mean age in this study was 67.4 years, which could account for the longer hospital stay. Risk factors such as history of coronary artery bypass graft (17.6%), diabetes mellitus and hypertension (33.3%) were also present in our patients and may have affected length of stay. When all patients were divided into bridge to transplantation or destination therapy groups, the bridge to transplantation group (8 patients) had a longer hospital length of stay than the destination therapy group (7 patients). Understanding the differences among options to LVAD implantation may contribute to improved preoperative patient selection and management.

Longer hospital length of stay is associated with the occurrence of adverse events. The INTERMACS reports investigated adverse events after LVAD implantation ([@b13-jer-15-3-481]). Early-onset adverse events after implantation included arrhythmias, tamponade, bleeding, and renal insufficiency, and late-onset adverse events included bleeding, right ventricular failure, infection, aortic valve pathology, thromboembolic events, and device failure ([@b6-jer-15-3-481]; [@b14-jer-15-3-481]; [@b13-jer-15-3-481]). Bleeding, cardiac arrhythmia, infection, and stroke were significant adverse events in postoperative year 1 ([@b15-jer-15-3-481]). The most frequent event after LVAD implantation was gastrointestinal bleeding in previous studies ([@b14-jer-15-3-481]; [@b27-jer-15-3-481]). We found that the primary adverse event was bleeding, followed by cardiac arrhythmia, and effusion during hospitalization. Bleeding was also the most common cause of adverse events after discharge in the present study. The types of adverse event were similar to those in the previous reports ([@b6-jer-15-3-481]; [@b15-jer-15-3-481]; [@b27-jer-15-3-481]). Preoperative older age (\>65 years) and ischemic etiology were significant risk factors for bleeding ([@b2-jer-15-3-481]). These factors may have been associated with the increased incidence of bleeding in our study. Patient selection for LVAD implantation should include screening for preoperative risk factors.

Readmission rate or frequency is an important clinical outcome, and several studies ([@b12-jer-15-3-481]; [@b28-jer-15-3-481]) have reported the average readmission frequency range of 1.34--1.79 per patient-year after discharge. The readmission frequency of 3.2 per patient-year in this study was slightly higher than that reported in previous studies. The mean time to first readmission was 57 days, which was longer than a previous report ([@b28-jer-15-3-481]) of 48 days but shorter than in a report by [@b12-jer-15-3-481]. The readmission frequency differed between implanted HeartMate-II or HeartWare devise ([@b8-jer-15-3-481]) but was not different between destination therapy and bridge to transplantation LVAD recipients ([@b3-jer-15-3-481]). Based on several studies ([@b3-jer-15-3-481]; [@b8-jer-15-3-481]; [@b10-jer-15-3-481]), we considered gastrointestinal bleeding to be a risk factor for the increased readmission rate in this study, and this risk factor was associated with older age in patients enrolled in this study.

The quality of life has become an important parameter in evaluating clinical outcomes in LVAD recipients. Several studies ([@b7-jer-15-3-481]; [@b11-jer-15-3-481]; [@b15-jer-15-3-481]; [@b21-jer-15-3-481]) demonstrated that quality of life after implantation was significantly improved in the physical and mental components. In our study, the quality of life measured at 12 months using the Minnesota Living with Heart Failure Questionnaire after implantation also showed improvement in both physical and mental components. Several factors, including right ventricular failure, female sex, and postoperative anxiety influenced quality of life after LVAD implantation ([@b11-jer-15-3-481]).

This study had some limitations. First, the number of patients was small and we did not perform follow-up in all patients who received an implanted LVAD due to the 1-year limit. Second, comparison of clinical outcomes according to the type or purpose of LVAD implantation was not performed due to the small sample size. Third, this report was based on a single-center study and generalization of the results should be cautious.

In conclusion, this single-center study demonstrated that LVAD implantation in Korean patients with heart failure is an effective option to improve clinical outcomes. However, further studies with longer follow-up are needed to confirm the effect of exercise therapy in a larger group of Korean patients.
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###### 

Baseline patient characteristics (n=15)

  Parameter                                  Value
  ------------------------------------------ -----------
  Age (yr)                                   67.4±11.6
                                             
  Sex                                        
   Male                                      10 (67)
   Female                                    5 (33)
                                             
  Body mass index (kg/m^2^)                  23.5±3.1
                                             
  Etiology of heart failure                  
   Dilated cardiomyopathy                    5 (33.3)
   Ischemic cardiomyopathy                   5 (33.3)
   Heart failure                             4 (26.7)
   Septic shock with STEMI                   1 (6.7)
                                             
  Previous cardiac intervention              
   Aortic valve replacement                  2 (13)
   Percutaneous coronary intervention        7 (41.2)
   Coronary artery bypass grafting           3 (17.6)
   Implantable cardioverter-defibrillation   2 (11.8)
   Permanent pacemaker                       2 (11.8)
   Cardiac resynchronization therapy         1 (5.9)
                                             
  NYHA functional classification             
   IV                                        6 (40)
   III                                       9 (60)
   II                                        0 (0)
   I                                         0 (0)
                                             
  LVEF (%)                                   23.6±11
                                             
  Other disease                              
   Hypertension                              5 (33.3)
   Diabetes mellitus                         5 (33.3)
   Chronic kidney disease                    5 (33.3)
   Chronic obstructive pulmonary disease     3 (20)
   Arrhythmia (Atrial fibrillation)          8 (53.3)
   Stroke                                    3 (20)

Values are presented as mean±standard deviation or number (%).

STEMI, ST elevation myocardial infarction; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction.

###### 

Adverse events in the hospital and after discharge

  Parameter                  Hospitalization   Discharge
  -------------------------- ----------------- -----------
  Bleeding                                     
   Gastrointestinal          5 (33.3)          6 (40)
   Nasal                     1 (6.7)           1 (6.7)
                                               
  Arrhythmias                                  0 (0)
   Ventricular tachycardia   6 (40)            0 (0)
   Atrial fibrillation       1 (6.7)           0 (0)
                                               
  Effusion                                     
   Pleural                   5 (33.3)          1 (6.7)
   Pericardial               1 (6.7)           0 (0)
                                               
  Pneumonia                  3 (20)            0 (0)
                                               
  Hematoma                   3 (20)            1 (6.7)
                                               
  Stroke                     1 (6.7)           2 (13.3)

Values are presented as number (%).

###### 

Clinical outcomes after implantation

  Parameter                           Mean±SD
  ----------------------------------- ------------
  Cardiac rehabilitation enrollment   
   Inpatient cardiac rehabilitation   64.5±82.1
                                      
  Length of stay day                  
   Total hospital                     103.7±51.7
   Total intensive care unit          25.3±17.5
                                      
  Time to first readmission (day)     57.2±124.1
                                      
  Readmission frequency               
   3 Months                           1.7±1.3
   6 Months                           2.2±2.1
   1 Year                             3.2±1.9

SD, standard deviation.
